Literature DB >> 28328318

Toward Discovery of Novel Microtubule Targeting Agents: A SNAP-tag-Based High-Content Screening Assay for the Analysis of Microtubule Dynamics and Cell Cycle Progression.

Nina Berges1, Katharina Arens1,2, Verena Kreusch1, Rainer Fischer1,3, Stefano Di Fiore1.   

Abstract

Microtubule targeting agents (MTAs) are used for the treatment of cancer. Novel MTAs could provide additional and beneficial therapeutic options. To improve the sensitivity and throughput of standard immunofluorescence assays for the characterization of MTAs, we used SNAP-tag technology to produce recombinant tubulin monomers. To visualize microtubule filaments, A549 cells transfected with SNAP-tubulin were stained with a membrane-permeable, SNAP-reactive dye. The treatment of SNAP-tubulin cells with stabilizing MTAs such as paclitaxel resulted in the formation of coarsely structured microtubule filaments, whereas depolymerizing MTAs such as nocodazole resulted in diffuse staining patterns in which the tubulin filaments were no longer distinguishable. By combining these components with automated microscopy and image analysis algorithms, we established a robust high-content screening assay for MTAs with a Z' factor of 0.7. Proof of principle was achieved by testing a panel of 10 substances, allowing us to identify MTAs and to distinguish between stabilizing and destabilizing modes of action. By extending the treatment of the cells from 2 to 20 h, our assay also detected abnormalities in cell cycle progression and in the formation of microtubule spindles, providing additional readouts for the discovery of new MTAs and facilitating their early identification during drug-screening campaigns.

Entities:  

Keywords:  SNAP-tag; cell-based assays; high-content screening; microtubule targeting agents; tubulin cytoskeleton

Mesh:

Substances:

Year:  2017        PMID: 28328318     DOI: 10.1177/2472555216685518

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  2 in total

1.  Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells.

Authors:  Mira Woitok; Diana Klose; Stefano Di Fiore; Wolfgang Richter; Christoph Stein; Gerrit Gresch; Elena Grieger; Stefan Barth; Rainer Fischer; Katharina Kolberg; Judith Niesen
Journal:  Onco Targets Ther       Date:  2017-07-06       Impact factor: 4.147

2.  Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing.

Authors:  Annelies Van Hemelryk; Lisanne Mout; Sigrun Erkens-Schulze; Pim J French; Wytske M van Weerden; Martin E van Royen
Journal:  Biomolecules       Date:  2021-10-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.